REG - IXICO plc - Scientific advisors & partners update

IXICOAnnouncement

Today 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260608:nRSH2178Ha&default-theme=true

RNS Number : 2178H  IXICO plc  08 June 2026

IXICO plc

("IXICO", the "Company" or the "Group")

 

IXICO EXPANDS RESEARCH COLLABORATIONS IN ALZHEIMER'S AND PARKINSON'S DISEASE

 

Professor Jeffrey Cummings and Professor Charles DeCarli in the field of
Alzheimer's Disease, and Professor Stéphane Lehéricy in the field of
Parkinson's Disease join the IXICO Scientific Advisory Board

 

Parkinson's disease research activities include collaboration with the Paris
Brain Institute and advisory role with The Michael J. Fox Foundation for
Parkinson's Research

 

 

08 June 2026, IXICO plc (AIM: IXI) - London, UK. IXICO, a global leader in
neuroscience imaging and biomarker analytics, using its AI-driven platform to
help advance drug development in neurological disorders, today announced it
has added three further global experts with Professor Cummings and Professor
DeCarli, leading KOLs in Alzheimer's Disease (AD) and, Professor Lehéricy a
leading KOL in  Parkinson's Disease (PD), to its Scientific Advisory Board.
IXICO also announced today that it has entered into two scientific R&D
initiatives in the field of PD.

 

 

Scientific Advisory Board Additions

 

Professor Jeffrey Cummings, MD, ScD, University of Nevada Las Vegas

Jeff is the Joy Chambers-Grundy Professor of Brain Science, Director of the
Chambers-Gundy Center for Transformative Neuroscience, Co-Director of the Pam
Quirk Brain Health and Biomarker Laboratory, Department of Brain Health,
School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV). A
full biography is available in the notes at the bottom of this announcement.

 

Professor Charles DeCarli, MD, University of California

Charles is Distinguished Professor of Neurology at the University of
California in Davis, California and recipient of the Victor and Genevieve Orsi
Chair in Alzheimer's Research. He is Co-Director of the UC Davis Alzheimer's
Disease Research Center (UCD ADRC), and Chief of the Imaging of Dementia and
Aging (IDeA) laboratory.  A full biography is available in the notes at the
bottom of this announcement.

 

Professor Stéphane Lehéricy, MD,  Paris Brain Institute

Stéphane Lehéricy is Professor of Neuroradiology and head of the
neuroradiology department at the Pitié-Salpêtrière Hospital (Paris) and
Director of CENIR (Centre de neuro-imagerie de recherche) at the Paris Brain
Institute. His area of research is the structural and functional study of the
normal and pathological human brain, including movement pathology and
neurodegenerative dementia.  A full biography is available in the notes at
the bottom of this announcement.

 

Scientific Collaborations

 

Paris Brain Institute

IXICO has entered into a research collaboration with the Paris Brain Institute
(ICM) to conduct a prospective  study evaluating a number of new
neuromelanin-sensitive MRI approaches as a potential imaging biomarker
approach for use in clinical research in PD. The study will focus on
optimising MRI acquisition protocols and applying advanced AI-driven analysis
to improve the robustness and reproducibility of this emerging imaging
technique, supporting its adoption as a quantitative imaging biomarker in PD
clinical trials.

 

The Michael J. Fox Foundation for Parkinson's Research (MJFF) - MRI Advisory
Committee

Robin Wolz, CSO/CMO at IXICO and Kirsi Kinnunen, Principal Biomarker Scientist
at IXICO have been invited to participate in  MJFF's MRI Advisory Committee,
which brings together researchers and experts working in neuroimaging and
biomarker research related to Parkinson's disease. The committee is part of a
broader precompetitive public-private effort that convenes academic leaders,
industry partners, and nonprofit stakeholders to advance the development,
standardisation, and validation of quantitative MRI biomarkers for PD
research. Through collaboration on protocols, data sharing, and
reproducibility, the committee supports the evaluation of imaging biomarkers
that could ultimately improve the measurement of disease progression and
therapeutic response in clinical trials.

 

Robin Wolz, Chief Scientific and Medical Officer of IXICO, commented:
"IXICO's business proposition is grounded in science, which is why working
with some of the world's most important KOLs ensures the validation and
clinical relevance of the services and technology we provide to the biopharma
industry. In addition, adding further expertise and collaborative R&D
activity, including our research collaboration with the Paris Brain Institute
and participation in MRI biomarker advisory activities, IXICO further deepens
its presence in the CNS space.

 

I'm delighted to welcome Jeff, Charlie and Stéphane to the Scientific
Advisory Board adding knowledge and experience to an already strong group of
advisors.  We will continue to explore opportunities to work with the most
important individuals and organisations pioneering progress towards better
understanding, diagnosis, and treatment of neurodegenerative disease."

 

 

Ends

 

For further information please contact:

 

 IXICO plc                                        +44 (0) 20 3763 7499
 Grant Nash, Chief Financial Officer

 James Chandler, Chief Business Officer

 Cavendish Capital Markets Limited                +44 (0) 20 7220 0500

 (Nominated Adviser and Sole Broker)
 Giles Balleny, Isaac Hooper (Corporate Finance)

 Nigel Birks (Healthcare Specialist Sales)

 Harriet Ward (Corporate Broking)

 Michael F Johnson (Sales)

 

 

About IXICO www.IXICO.com (http://www.IXICO.com)

IXICO is a global leader in neuroscience imaging and biomarker analytics,
using its proprietary AI-driven platform to help advance the treatment of
neurological disorders and reduce the uncertainties associated with drug
discovery, development and monitoring.   As a key part of the global
neurological disease research community, the Company has built a global
reputation and 20-year track record as an end-to-end Imaging Contract Research
Organisation (iCRO) working with leading pharma companies, innovative
biotech's, disease consortia and non-profit organisations. IXICO has supported
hundreds of neurological clinical trials, analysed hundreds of thousands scans
and built an expansive network of expert imaging centres around the world.

 

The IXICO Platform is tailor-made for neurological disease, reliably
processing data from global trials, precisely measuring key imaging biomarkers
associated with the identification, progression and treatment of diseases such
as Alzheimer's, Huntington's and Parkinson's.  Image data is interrogated by
the Platform and IXICO's expert scientists translating complex data into
clinically meaningful while minimizing data variability and increasing
reproducibility.

 

Professor Jeffrey Cummings, MD, ScD, University of Nevada Las Vegas

Jeff is the Joy Chambers-Grundy Professor of Brain Science, Director of the
Chambers-Gundy Center for Transformative Neuroscience, Co-Director of the Pam
Quirk Brain Health and Biomarker Laboratory, Department of Brain Health,
School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV).
Dr Cummings is globally recognized for his contributions to Alzheimer's
research, drug development, and clinical trials. Dr Cummings interests embrace
clinical trials, developing new therapies for brain diseases, and the
interface of neuroscience and society. He has authored or edited 43 books and
published over 800 peer-reviewed papers.

 

Dr Cummings was formerly Augustas Rose Professor of Neurology and Professor of
Psychiatry at UCLA, Director of the Mary S. Easton Center for Alzheimer's
Disease Research at UCLA, Director of the Deane F. Johnson Center for
Neurotherapeutics at UCLA, and Director of the Cleveland Clinic Lou Ruvo
Center for Brain Health. He is past president of the Behavioural Neurology
Society and of the American Neuropsychiatric Association.

 

Professor Charles DeCarli, MD, University of California

Charles is Distinguished Professor of Neurology at the University of
California in Davis, California and recipient of the Victor and Genevieve Orsi
Chair in Alzheimer's Research. He is Co-Director of the UC Davis Alzheimer's
Disease Research Center (UCD ADRC), a United States National Institutes of
Health funded Alzheimer's research centre. He is also Chief of the Imaging of
Dementia and Aging (IDeA) laboratory.

 

His research focuses on using advanced structural and functional brain imaging
to study normal aging, mild cognitive impairment and dementia and the role of
genetics, diversity, cerebrovascular and Alzheimer's disease on these
processes. He is a recipient of the J. Allyn Taylor International Prize in
Medicine-Imaging of the Aging Brain in recognition of his work.

 

Professor Stéphane Lehéricy, MD,  Paris Brain Institute

Stéphane Lehéricy is Professor of Neuroradiology and head of the
neuroradiology department at the Pitié-Salpêtrière Hospital (Paris) and
Director of CENIR (Centre de neuro-imagerie de recherche) at the Paris Brain.
His area of research is the structural and functional study of the normal and
pathological human brain, including movement pathology and neurodegenerative
dementia. He focuses on the functional anatomy of the ganglia at the base of
the normal human brain and on movement disorders. He has contributed to the
understanding of the functional anatomy of the basal ganglia using fMRI and
the diffusion tensor.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDGCGDLXBGDGLU



            Copyright 2019 Regulatory News Service, all rights reserved